Analyzing Device-Associated Infections and Mortality in CKD Patients Receiving CIED

The following is a summary of “Device-related infection and mortality in patients with chronic kidney disease receiving cardiac implantable electronic devices: a propensity score-matched cohort study,” published in the November 2023 issue of Infectious Disease by Wu et al.

Researchers started a retrospective study to determine the effect of bundled skin antiseptic preparation on preventing cardiac implantable electronic device (CIED) infection in patients with chronic kidney disease (CKD).

They comprised 1,668 patients (July 2012 and December 2019) who received CIEDs. These patients were classified into two groups based on their CKD diagnosis: a group with CKD (n = 750, 45%) and a group without CKD (n = 918, 55%). The primary outcome was clinical CIED infection, covering major and minor infections, with secondary outcomes including cardiovascular mortality and all-cause mortality. Applied propensity score matching (PSM) to alleviate selection bias between the study groups.

The results showed that during a 4-year follow-up period, CIED infection occurred in 30 patients (1.8%). Following PSM, the incidence of CIED infection was comparable between patients with CKD and without CKD (1.0% vs. 1.8%). Patients with CKD exhibited higher incidences of cardiovascular mortality and all-cause mortality compared to those without CKD (6.5% vs. 3.0%, P=0.009; 22.8% vs. 11.8%, P<0.001, respectively).

Investigators concluded that CKD patients had similar CIED infection rates to non-CKD patients after using bundled skin antiseptics but had higher mortality rates.

Source: bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08773-0